ARTICLE | Product Development
The new modality pipeline against ANGPTL3 grows with Verve’s new program
At least two gene editing therapies and three RNA therapies against ANGPTL3 set to compete in dyslipidemia indications
August 23, 2022 12:17 AM UTC
Verve is joining a short list of new modality companies moving toward the clinic with therapies against ANGPTL3, a cardiovascular disease target rising in popularity as new technologies create new strategies to disrupt its expression.
Verve Therapeutics Inc. (NASDAQ:VERV) announced the nomination of VERVE-201 as its second product candidate on Monday, following last month’s announcement that its PCSK9-targeting therapy became the first base-editing therapy to enter the clinic...
BCIQ Target Profiles